Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 16, 2025, details corporate governance actions taken by Citius Pharmaceuticals, Inc. to facilitate a proposed increase in authorized common stock. The Company is incorporated in Nevada and trades on The Nasdaq Capital Market under the symbol CTXR.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The only financial transaction disclosed is the issuance of one share of Series A Preferred Stock to the Company's Chairman and CEO, Leonard Mazur, for a purchase price of $100.
Material Changes and Corporate Actions
- Authorized Share Increase Proposal: The Company is seeking stockholder approval to increase authorized common stock from 16,000,000 to 250,000,000 shares.
- Series A Preferred Stock Issuance: On April 17, 2025, the Company issued one share of Series A Preferred Stock to Leonard Mazur. This share carries 1,000,000,000 votes exclusively for the purpose of voting on the Authorized Share Increase. It has no economic rights (no dividends, no liquidation preference) and is not convertible.
- Voting Mechanism: The Series A Preferred Stock will vote in the same proportion as the aggregate votes cast by common stockholders on the share increase proposal. It will be automatically redeemed for $100 immediately after the final vote results are announced.
- Bylaws Amendment: Effective April 16, 2025, the Board amended the Bylaws to reduce the quorum requirement for stockholder meetings from a majority (50% + 1) to one-third (1/3) of outstanding voting power. This change aims to reduce the risk of meeting adjournments and associated costs.
Outlook, Risks, and Management Commentary
Management views the Bylaws Amendment as a risk mitigation strategy to prevent the failure to achieve a quorum, which could lead to adjournments, increased proxy solicitation costs, and business disruptions. The issuance of the Series A Preferred Stock is a procedural mechanism to ensure the voting outcome on the share increase aligns with the common stockholder vote, effectively neutralizing the impact of the preferred shares on the final tally while securing the vote count.
Key Facts for Investor Verification
- Verify the outcome of the Special Meeting regarding the increase of authorized shares from 16 million to 250 million.
- Confirm the redemption of the Series A Preferred Stock and the return of the $100 purchase price to Leonard Mazur post-vote.
- Review the preliminary proxy statement for details on the rationale behind the significant increase in authorized shares.
- Note that the Series A Preferred Stock has no economic value beyond the voting mechanism and the $100 redemption price.